← Back to all trials
Recruiting
NCT05683626
Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital
Conditions: Uveitis
Sex: All
Ages: 18 Years – 40 Years
Enrollment: 40
Sponsor: Sohag University
Location: Egypt
Summary
the goal of this prospective cohort study is to asses the Safety and efficacy of Adalimumab therapy for treatment of Behcet's disease-related uveitis in adult patients at sohag university hospital.Patients will receive adalimumab (40 IU), subcutaneous injection every two weeks for 6 months either as a primary treatment or if refractory to corticosteroids and at least one conventional synthetic immunosuppressive drug.
Eligibility Criteria
Inclusion Criteria:Adult patients with complete Behçet's disease associated uveitis .Exclusion Criteria:Any patient with HIV, HBV, HCV, syphilis, toxoplasma, tuberculosis or other infections; liver, renal, cardiac or demyelinating diseases as well as substance abuse and malignancies will be excluded from the study
Source: ClinicalTrials.gov (NCT05683626). StuddyBuddy aggregates publicly available trial information.
